Virax Biolabs Group Limited (VRAX) — DCF ValuationDiscounted Cash Flow intrinsic value with Bear, Base & Bull scenarios
Virax Biolabs Group Limited (VRAX)
Market cap ($0.00B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.
Alternative Approach:
Use relative valuation (P/E, P/S) vs. peer group.
Insufficient data to compute DCF valuation for VRAX. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For VRAX, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.